Investor Kit

Company Profile

Founded in 1995, Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders.

Acorda markets three FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve walking in patients with multiple sclerosis (MS), as demonstrated by an increase in walking speed. The Company has one of the leading pipelines in the industry of novel neurological therapies. Acorda is currently developing a number of clinical and preclinical stage therapies. This pipeline addresses a range of disorders including post-stroke walking deficits, Parkinson’s disease, epilepsy, neuropathic pain, heart failure, MS, and spinal cord injury.

Stock Chart


Date Filing Description Download
11/23/15 4 Statement of Changes in Beneficial Ownership
11/09/15 10-Q Quarterly Report
11/06/15 4 Statement of Changes in Beneficial Ownership
10/30/15 SC 13G Statement of Ownership

Stock Quote

ACOR (Common Stock) $ 38.19 +0.00 (+0%) Volume: 393,827 MORE November 30, 2015

Email Alerts

Un-subscribe from email alerts
Email Address *
Mailing Lists *